Occam Recruits David Moller as Chief Scientific Officer of Variant Bio
Variant Bio, a genomics-driven drug discovery company backed by Lux Capital, General Catalyst, Alta Partners, SoftBank, and Casdin Capital, announced David Moller, MD as Chief Scientific Officer.
In Moller, Variant captures a broadly gauged and versatile drug discovery and development leader with over two decades of experience presiding over R&D in both big pharma and biotech, including Eli Lilly and Merck. He brings with him a deep understanding of and facility for transmuting complex genetic insights into innovative therapeutic programs, a knowledge that will doubtlessly enable Variant to deliver on its substantial potential as a transformative genomics-based drug discovery and development organization.
View recent Placements
.jpg)
.jpg)
.jpg)
.jpg)
DISCOVER OCCAM GLOBAL
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies.
Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.